Latest Content

FDA grants accelerated approval to camizestrant with a CDK4/6 inhibitor for adult patients with ESR1-mutated HR+/HER2- advanced breast cancer.

Phase 3 NRG-GU005 trial shows SBRT limits bowel complications and fatigue compared to MH-IMRT, but does not improve disease-free survival rates.

Oncology nursing guide to the FDA approval of zanidatamab-hrii for HER2+ gastroesophageal cancers, featuring insights from Joe Chichioco, RN, MPH.

Beth Sandy, CRNP, of Penn Medicine explains how oncology nurses and pharmacists collaborate to manage financial toxicity and secure oral therapies.

Experts share critical clinical protocols for managing daraxonrasib (Rasonque) following its landmark FDA approval.

Study of breast cancer survivors shows that depression and stress, rather than cardiac function decline, are the primary drivers of long-term fatigue.

FDA approves rusfertide (Mimrylo), a first-in-class hepcidin mimetic that regulates iron to control erythrocytosis in patients with polycythemia vera.

New ASCO living guideline establishes standard-of-care frameworks for recurrent ovarian cancer, highlighting biomarkers and treatment sequencing.

Oncology nurses share high-level strategies for advanced RCC therapy, focusing on managing hypertension, diarrhea, and fatigue in the frontline.

Surbhi Sidana, MD, discusses how the FDA-approved oral CELMoD iberdomide expands access and impacts nursing care in multiple myeloma.

Sarah Cannon's Kelsey Martin, APRN, AOCNP, discusses managing toxicities, nursing collaboration, and tailored treatment sequencing in frontline mTNBC.

A new study shows physical activity increases tumor-killing T cells and reduces suppressive Tregs in obese lung environments, boosting outcomes.

At the 29th APAO Symposium, Mark Honor, PA-C, discussed the collaborative care model and the vital role of PAs in managing day-to-day oncology care.